Surveillance of Vancomycin-resistant Enterococci colonization with GeneXpert vanA/vanB test and culture method by Hatice Uludağ Altun et al.
Correspondence: Hatice Uludağ Altun, Turgut Özal University Hospital, Department of Medical Microbiology, Beştepe, 
Yenimahalle, Ankara, Turkey     Email: haticeuludag80@yahoo.com 
Received: 02 December 2013, Accepted: 12 May 2014 
Copyright © Journal of Microbiology and Infectious Diseases 2014, All rights reserved
Journal of Microbiology and Infectious Diseases /  2014; 4 (3): 97-101
JMID   doi: 10.5799/ahinjs.02.2014.03.0147
RESEARCH ARTICLE
Surveillance of Vancomycin-resistant Enterococci colonization with 
GeneXpert vanA/vanB test and culture method
Hatice Uludağ Altun1,2, Çiğdem Ataman Hatipoğlu2, Cemal Bulut2, Server Yağcı2,3, Günay Tuncer Ertem2, 
Sami Kınıklı2, Ali Pekcan Demiröz2
1 Turgut Özal University Hospital, Department of Medical Microbiology, Ankara, Turkey
2 Ankara Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey
3 Pamukkale University, Department of Medical Microbiology, Denizli, Turkey
ABSTRACT
Objectives: Early detection of vancomycin resistant enterococci (VRE) colonization in hospitalized patients plays an im-
portant role in controlling enterococcal infections. For this purpose, the detection of VRE from rectal swab specimens 
can be performed with various methods.
Methods: In this study, VRE colonization in the rectal swab samples of patients from intensive care units, burn unit, and 
infectious diseases clinic in our hospital were evaluated. In total, 2,394 rectal swab samples from 1,627 patients were col-
lected between January 2012 and 2013. A commercial product (Enterococcosel agar) was used for cultivating, and the 
growing bacteria were identified with conventional methods and/or the VITEK 2 Compact system (BioMerieux, France). 
The samples of the patients transferred from another hospital and who had a history of VRE infection or carriage were 
examined with an automated real-time PCR system (Gene Xpert™ vanA/vanB, Cepheid, Sunnyvale, CA).
Results: A total of 59 (3.6%) patients were positive for VRE, 25 were diagnosed with PCR, and 34 were diagnosed with 
culture methods. Among the samples identified by PCR, 19 were only vanA harboring VRE, five were only vanB har-
boring VRE, and one was both vanA and vanB harboring VRE. All of the VRE isolates were identified as E. faecium. The 
number of patients administered with vancomycin therapy before being diagnosed with VRE was 11(18.6%). 
Conclusions: It is important to determine the appropriate surveillance method for the early diagnosis of VRE carriers 
among patients at risk according to their patient profile, needs, and resources. J Microbiol Infect Dis 2014; 4(3): 97-101
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GeneXpert vanA/vanB testi ve kültür metodu ile Vankomisin dirençli Enterokok 
kolonizasyonunun sürveyansı
ÖZET
Amaç: Hastanede yatan hastalarda vankomisin dirençli enterokok (VRE) kolonizasyonunun erken tespiti, enterokok 
enfeksiyonlarının kontrolünde önemli bir yer tutmaktadır. Bu amaçla rektal sürüntü örneklerinde çeşitli yöntemlerle VRE 
tespiti yapılabilmektedir.
Yöntemler: Bu çalışmada hastanemizde Ocak 2012-2013 tarihleri arasında, yoğun bakım ünitelerinde, yanık ve enfeksi-
yon hastalıkları kliniklerinde yatmakta olan 1627 hastaya ait 2394 rektal sürüntü örneğinde VRE kolonizasyonu araştırıldı. 
Bu amaçla kültür için Enterokokosel agar kullanıldı. Üreyen bakteriler konvansiyonel yöntemler ve/veya VITEK 2 Compact 
(BioMerieux, Fransa) ticari sistemi kullanılarak tür düzeyinde tanımlandı. Başka bir hastaneden nakil gelen ve daha önce 
VRE enfeksiyonu veya taşıyıcılığı öyküsü olanlarda rektal örnekler otomatize gerçek zamanlı polimeraz zincir reaksiyonu 
(Realtime PCR) cihazı (Gene Xpert™ vanA/vanB, Cepheid, Sunnyvale, CA) ile incelendi.
Bulgular: Toplam 59 hastada VRE pozitifliği (%3,6) saptandı. Bunların 25’i PCR, 34’ü ise kültür ile çalışıldı. PCR ile tanı ko-
nulanlardan 19’u vanA pozitif, 5’i vanB pozitif, biri ise vanA+vanB pozitif olarak saptandı. Vankomisin dirençli enterokok 
olarak belirlenen tüm suşlar E. faecium olarak tanımlandı. Hastalardan 11(%18.6)’nın VRE tanısı öncesinde tedavisinde 
vankomisin kullandığı saptandı.
Sonuç: Riskli hastalarda VRE taşıyıcılığını erken dönemde saptayabilmek için her hastanenin kendi hasta profiline, ihti-
yaçlarına ve kaynaklarına göre uygun sürveyans yöntemini belirlemesi gerektiğini düşünmekteyiz.
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INTRODUCTION
Vancomycin-resistant enterococci (VRE) are impor-
tant pathogens causing nosocomial epidemics and 
an increase in mortality and morbidity, especially in 
intensive care units. It is important to monitor infec-
tion in patients colonized with VRE and to prevent 
the spread of the infection to other patients.1 One 
of the most important components of a successful 
VRE control program is the detection of gastroin-
testinal colonization. This is due to the fact that the 
most important VRE reservoirs are the patients that 
carry VRE in their gastrointestinal systems.2 Thus, 
obtaining perirectal swab samples at regular inter-
vals is the gold standard in the determination of 
VRE.3 The current study aimed the retrospective 
evaluation of VRE colonization in rectal swab sam-
ples that were obtained from the patients who were 
hospitalized in intensive care units (ICUs), the Burn 
Unit and Infectious Disease Clinics of our hospital 
within the scope of surveillance.
METHODS
Patients, units, schedule of taking samples
Surveillance was conducted in all ICUs in the hospi-
tal in order to diagnose patients colonized with VRE 
by taking rectal swab samples not only from regular 
patients, but also from newly hospitalized patients 
once a month during their hospitalization period. 
In ICUs in which VRE colonization was detected, 
weekly surveys of VRE were conducted. When all 
collected perirectal cultures were found to be nega-
tive successively for four weeks, this procedure was 
terminated and surveillance was conducted once a 
month instead of per week. If a VRE positive patient 
was transferred from an ICU to a clinic, the weekly 
surveillance continued in his/her clinic room and 
the abovementioned procedure was performed in 
the same way. Although routine VRE surveillance 
is generally not conducted in Burn Units and Infec-
tious Disease clinics within our hospital, this study 
also covers these units, as the patients were trans-
ferred to these clinics after having been diagnosed 
with VRE upon their hospitalization in ICUs. 
A total of 2,394 rectal swab samples taken from 
1,627 patients who were hospitalized in the ICUs, 
Burn Unit, and Infectious Disease clinic between 
January 2012 and January 2013 were included 
in the study. The samples were transported to the 
laboratory in Amies transport medium. The study 
was carried out in the Infectious Disease and Clini-
cal Microbiology laboratory. The rectal swabs that 
were taken for monthly surveys were studied using 
culture methods. 
Laboratory methods
The rectal swab samples taken from patients who 
were transported from another hospital or patients 
with VRE infection in their medical history or carri-
ers of VRE were studied using a multiplex real-time 
PCR (Gene Xpert™ vanA/vanB, Cepheid, Sunny-
vale, CA) device. After mixing the sample with the 
reagent according to the recommendations of the 
manufacturer, the rectal swab samples for PCR 
study were vortexed for 1 minute. This mixture was 
added to a single-use only cartridge. The cartridge 
was placed in the device. The Gene Xpert™ Dx 
module was selected and executed. The results 
were reported as vanA and vanB positive or nega-
tive. The results that were vanB positive were stud-
ied again according to the recommendations of the 
manufacturer. The samples that were evaluated as 
vanA and vanB positive were confirmed with cul-
tures.
For culture, the samples were cultivated in BBL 
enterococcosel agar (Becton Dickinson, USA) in 
which 6μg/ml vancomycin and 1 μg/ml meropenem 
were added. They were incubated in aerobic condi-
tions at 37°C for 72 hours. The bacterial growth was 
controlled daily. Esculin-positive black colored colo-
nies were tested with gram staining, catalase, and 
growth tests in the medium containing 6.5% NaCI. 
The pure cultures of the colonies that were 
gram-positive, catalase negative, hydrolyzed 
esculin, and grew in a medium containing 6.5% 
NaCl were sub-cultured on 5% sheep blood agar. 
The growing bacteria were defined in species level 
by using conventional methods and VITEK 2 Com-
pact (BioMerieux, France) system. The resistance 
of strains that were detected as vancomycin-resis-
tant by VITEK-2 was confirmed by using vancomy-
cin and teicoplanin E-test in accordance with the 
recommendations of CLSI.4 The repeated rectal 
swab samples, as part of the weekly survey, of the 
patients that were found to be VRE positive with 
PCR were studied with culture again.
RESULTS
A total of 2,394 rectal swab samples taken from 
1,627 patients between January 2012 and Janu-
ary 2013 were included in the study. Of all of the 
samples, 437 (18.2%) were samples taken from pa-
tients hospitalized in the neonatal ICU, 349 (14.6%) 
were in the pediatric ICU, 453 (18.9%) were in the Uludağ Altun H, et al. GeneXpert vanA/vanB test and culture method 99
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anesthesiology ICU, 464 (19.4%) were in the neu-
rosurgical and reanimation ICU, 324 (13.5%) were 
in the neurology ICU, 338 (14.1%) were in internal 
medicine ICU, 22 (0.9%) were in the burn unit, and 
7 (0.2%) were those in the infectious diseases de-
partments.
Vancomycin resistant enterococci were de-
tected in 124 of a total of 2394 rectal samples. The 
repeated positive results detected in the same pa-
tient were eliminated and then a total of 59 patients 
samples that were VRE positive (3.6%) were evalu-
ated. When the epidemiological data of the VRE-
positive patients were evaluated, it was determined 
that six were children and 53 were adults. Thirty-
six (61%) of the patients were female and 23 (39%) 
were male. The mean age of adult patients was 64.6 
years (range: 30-94 years) and the mean age of the 
pediatric patients was 1.5 years (range: 1-2 years). 
It was found that 11 (18.6%) patients used vanco-
mycin treatment prior to the diagnosis of VRE. 
Table 1. The distribution of culture and PCR positivities of 
rectal swab samples according to the departments.
Unity n (%) Culture(+)* PCR (+)* Total
NSICU 464 (19.4) 1 8 9
ARICU 453 (18.9) 15 6 22
NBICU 437 (18.2) 2 1 3
PICU 349 (14.6) - 1 1
NICU 324 (13.5) 3 5 8
IMICU 338 (14.1) 13 - 13
Burn Unit  22 (0.9) - 1 1
Infectious 
diseases 7 (0.3) - 3 3
TOTAL 2394 34 25 59
n: Number of rectal swab samples; *Only one of the re-
peated culture/PCR positivities for each patient was eval-
uated; NSICU: Neurosurgical ICU; ARICU: Anesthesiol-
ogy and Reanimation ICU; NBICU: Neonatal ICU; PICU: 
Pediatric ICU; NICU: Neurology ICU; IMICU: Internal 
Medicine ICU
It was determined that out of total 59 patients, 
18 (30.5%) had neurological disorders (central ner-
vous system disorders, such as cerebrovascular 
disease, epilepsy, or hydrocephalus), 13 (22%) had 
nephrologic diseases (chronic renal failure, acute 
renal failure), seven (11.8%) had congestive heart 
failure, eight (13.5%) had respiratory system dis-
eases (pneumonia, chronic obstructive pulmonary 
disease), and four (6.7%) had orthopedic problems 
(traffic  accident,  femur  fracture,  or  cervical  disc 
pathologies), two (3.3%) had acute abdomen, and 
nine (15.2%) had other diseases (ovarian carcino-
ma, suicide, fever of unknown origin, or gastrointes-
tinal hemorrhage).
Vancomycin resistant enterococci positivity 
was detected with PCR in 25 (42.3%) patients and 
with cultures in 34 (57.6%) patients out of 59 pa-
tients. Among the samples that the diagnosis was 
done with PCR, one was vanA+vanB positive, five 
were vanB positive, and 19 were vanA positive. All 
VRE positive strains were defined as E. faecium. 
The VRE positivity of rectal swab samples that 
was detected by culture and PCR is presented in 
Table 1.
DISCUSSION
Surveillance studies are very important in the detec-
tion of VRE colonization. In our hospital, routine sur-
veillance is performed in ICUs for the early detec-
tion of patients that are colonized with VRE and for 
immediate implementation of the necessary contact 
isolation precautions. 
When VRE colonization was detected, weekly sur-
veys of VRE began. When all of the perirectal cul-
tures that were taken consecutively for four weeks, 
become negative, surveillance studies were con-
ducted once a month.5 
In previous studies, it was mentioned that the 
risk factors for VRE colonization were linked with 
long hospitalization process, medical history of hos-
pitalization in intensive care, dialysis and transplan-
tation units, renal failure, enteral feeding, hemato-
logical malignancies, neutropenia, antibiotic use 
(especially cephalosporins, antibiotics effective on 
anaerobes, quinolone, and vancomycin), contact 
with VRE positive patients, or the health care per-
sonnel who attend to these patients, and medical in-
struments contaminated with VRE.6-9 In the current 
study, there were risk factors consistent with this 
data. Most of the patients were hospitalized in the 
ICU, acute or chronic renal failures were present in 
22% of the patients. There was a history of vanco-
mycin use before the diagnosis of VRE in 18.6% of 
cases. Different from the previous studies, 30.5% of 
the patients in the present study had neurological 
diseases.
In a study that was conducted on 2,115 patients 
in the USA, the rate of VRE colonization was found 
to be 4.7%, and in another study11 on 1,362 patients Uludağ Altun H, et al. GeneXpert vanA/vanB test and culture method 100
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this value was found to be 10%. VRE colonization 
was detected at a rate of 2%12 in 624 patients in 
Holland, and at a rate of 3.5%13 in 636 patients in 
Belgium. In the studies from Turkey, Ergani Özcan 
et al.14 reported the VRE colonization rate as 1.5% 
in 2,488 rectal swab samples, whereas Aygün et 
al.15 reported this rate as 1.9% in 467 patients. In 
the current study, the rate of VRE colonization in our 
hospital was found to be 3.6%. Although this rate is 
lower than the data in the United States, it is found 
to be consistent with Europe and Turkey.
The resistance of enterococci to glycopep-
tide antibiotics was first reported by Uttley et al.16 
in 1988. There are six types of resistance genes 
among enterococci: A, B, C, D, E, and G. While 
the strains with the vanA phenotype had high lev-
els of resistance to vancomycin and teicoplanin, 
those with the vanB phenotype were moderately or 
highly resistant to vancomycin and were sensitive 
to teicoplanin.17 The resistance in both phenotypes 
is transferrable to other species and inducible. In 
studies that were conducted with human-induced 
enterococci in Turkey, the most frequently detected 
resistance phenotype was vanA.14,18-20 In the cur-
rent study, the researchers also detected the vanA 
phenotype most frequently (76%). Although vanB 
resistance is rarely seen in Turkey, it was first de-
tected by Coşkun et al.21 in an E. faecium strain. In 
the current study, the positivity of vanA and vanB 
together was seen in one (1.69%) strain and vanB 
positivity was detected in five (8.4%) strains. Some 
studies have shown that some anaerobic bacteria 
other than enterococci (such as Clostridium bolte-
ae, C. hathewayi, C. innocuum-like, C. lavalense, 
C. symbiosum, Eggerthella lenta, and Ruminococ-
cus lactaris-like, C. clostridioforme and Atopobium 
minutum) may also cause vanB positivity in rectal 
samples.22-26 Thus, it is important to confirm the re-
sults with the cultures in strains that were detect-
ed as only vanB positive. In the current study, the 
samples that were detected as vanB positive were 
examined with PCR again and the positive samples 
were confirmed with cultures.
VRE positivity was detected with PCR at a rate 
of 42.3% and 57.6% was detected with cultures. 
In the current study, as PCR and culture methods 
were not used together in the same sample, the su-
periority of the two methods in the detection of VRE 
could not be compared.
The use of the PCR method in the detection 
of glycopeptide resistance was first defined by Dut-
ka-Malen et al.27 in 1995. Today the use of PCR in 
clinical microbiology laboratories for the detection of 
VRE has gradually increased. The detection of VRE 
with culture takes 2-4 days. There are advantages 
of PCR over culture, such as saving time required 
for the detection of VRE and providing the applica-
tion of control interventions in a shorter time. Gene 
Xpert™ is a real-time device in which the lysis, ex-
traction, amplification, and detection procedures are 
performed by using a single-use only cartridge.28 The 
time to obtain results takes 45 minutes and provides 
the opportunity to take immediate precautions after 
isolation. In a study by Gazin et al.29 in which they 
compared different PCR methods, they found that 
the Gene Xpert™ device is effective in the detection 
of VRE in low concentrations such as 10-100 CFU/
ml. In another study, the sensitivity, specificity, posi-
tive predictive value, and negative predictive value 
of this device were reported as 96.4%, 93%, 92%, 
and 96.9%, respectively.30 The PCR method is a fa-
vored method, as it yields the results within a short 
period of time. However, this method is costly and it 
was applied to patient groups who were transferred 
from another hospital or who had a previous medi-
cal history of VRE infection or who were carriers. 
Recently, acquired antibiotic resistance has 
been observed in enterococci. It is important to de-
tect VRE colonization early in hospitalized patients 
to control infections. The current study detected 
42.3% of VRE colonization with PCR and 57.6% 
with the culture method. However, the PCR and 
culture methods were not applied together, as this 
study did not aim to compare the two methods. In 
conclusion, each hospital should determine the ap-
propriate surveillance method according to their pa-
tient profile, needs, and the sources for the early 
detection of VRE porters in high risk patients.
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